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Background. Pretreatment with the angiotensin-converting inhibitor captopril or volatile anesthetic isoflurane has, respectively,
been shown to attenuate myocardial ischemia reperfusion (MI/R) injury in rodents and in patients. It is unknown whether or not
captopril pretreatment and isoflurane preconditioning (Iso) may additively or synergistically attenuate MI/R injury. Methods and
Results. Patients selected for heart valve replacement surgery were randomly assigned to five groups: untreated control (Control),
captopril pretreatment for 3 days (Cap3d), or single dose captopril (Cap1hr, 1 hour) before surgery with or without Iso (Cap3d+Iso
andCap1hr+Iso). RabbitMI/Rmodel was induced by occluding coronary artery for 30min followed by 2-hour reperfusion. Rabbits
were randomized to receive sham operation (Sham), MI/R (I/R), captopril (Cap, 24 hours before MI/R), Iso, or the combination
of captopril and Iso (Iso+Cap). In patients, Cap3d+Iso but not Cap1hr+Iso additively reduced postischemic myocardial injury and
attenuated postischemic myocardial inflammation. In rabbits, Cap or Iso significantly reduced postischemic myocardial infarction.
Iso+Cap additively reduced cellular injury that was associated with improved postischemic myocardial functional recovery and
reduced myocardial apoptosis and attenuated oxidative stress. Conclusion. A joint use of 3-day captopril treatment and isoflurane
preconditioning additively attenuated MI/R by reducing oxidative stress and inflammation.
1. Introduction
Myocardial ischemia reperfusion (MI/R) injury is a major
perioperative complication that is associated with significant
morbidity and mortality in coronary artery bypass graft
(CABG) surgery [1, 2] and in patients undergoing heart
valve replacement surgery [3] using cardiopulmonary bypass
(CPB), especially in patients with comorbidities (e.g., age
[4] and diabetes [5]). Volatile anesthetic preconditioning
(e.g., isoflurane preconditioning, Iso) provides cardioprotec-
tive effects during CABG [6, 7]. Given that the isoflurane
preconditioning cardioprotection is optimal or effective only
when duration of the index ischemia is limited within 25–
40 minutes [8] while the typical period of cardiac ischemia
during CABG surgery is usually longer than 60 minutes, the
cardioprotective potential of Iso in the clinical settings is
limited. Moreover, in aging [9] and diabetes [10], in which
myocardial oxidative stress and inflammation are increased
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concomitant with reduced endogenous antioxidant capacity,
cardioprotection of Iso is diminished or abolished.
Increased systemic oxidative stress induced by robust
production of reactive oxygen species (ROS) has been sug-
gested as themain causewhich adversely affects postoperative
cardiac functional recovery in patients undergoing CABG
surgery using CPB [11]. ROS not only increases oxidative
stress by increasing lipid peroxidation but also reduces
myocardial antioxidant capacity by diminishing endogenous
antioxidant enzymes activities (e.g., superoxide dismutase)
[12, 13]. In addition, proinflammatory cytokines release (e.g.,
tumor necrosis factor- (TNF-) 𝛼) is also enhanced after
CPB [14], which may further increase ROS production and
exacerbate myocardial function [15]. Experimental studies
show that Iso confers cardioprotection againstmyocardial IRI
by stimulating the generation of small amount of ROS which
triggers cardiac protective signaling pathways [16, 17]. On the
other hand, experimental studies showed that volatile anes-
thetic preconditioning exert cardioprotective effects against
myocardial ischemic reperfusion injury through reducing
nuclear factor- (NF-) kB-dependent inflammatory gene
expression and decreasing TNF-𝛼 production [18, 19].
Captopril, an angiotensin-converting enzyme (ACE) in-
hibitor, has been shown to be cardioprotective in the preven-
tion and regression of left ventricular hypertrophy or atten-
uation of MI/R injury in both clinical [20] and experimental
settings [21]. Captopril pretreatment exerts cardioprotective
effects by increasing tissue antioxidant activity, scavenging
different types of ROS, and thus prevents lipid peroxida-
tion [22, 23]. Captopril by inhibiting angiotensin-converting
enzyme activity reduced the degradation of bradykinin,
resulting in enhanced formation of prostacyclin and nitric
oxide, and in turn increases myocardial antioxidant and
anti-inflammatory properties [20, 24] and confers cardiopro-
tective effects [25]. Therefore, the mechanism of captopril
cardioprotection is totally different from that of isoflurane
preconditioning. Thus, it is plausible that captopril in com-
bination with isoflurane preconditioning may synergistically
or additively attenuateMI/R in clinical settings.Therefore, we
hypothesized that alternative use of captopril pretreatment
and isoflurane preconditioning may confer superior protec-
tion againstMI/R injury to either isoflurane or captopril regi-
men alone and that themechanism of the additive/synergistic
effect is related to reducing cardiomyocytes apoptosis and
myocardial oxidative stress.
2. Methods
2.1. Patient Population and Study Design. The clinical trial
was carried out in accordance with the Declaration of
Helsinki (2000) of the World Medical Association. The study
protocol was approved by the institutional ethics committee.
All subjects gave written informed consent after having been
given full explanation of the purpose, nature, and risk of all
procedures used.
After obtaining written informed consent, 100 ASA
(American Association of Anesthesiologists) class II to III
patients, aged 38–55 years, presenting for scheduling for heart
mitral valve replacement surgery were assigned according
to a computer-generated random code to one of the five
groups: a control group receiving midazolam and fentanyl
(group control; 𝑛 = 20); captopril pretreatment for 1 hour
(Cap1hr, 12.5mg, oral administration) or 3 days (Cap3d,
12.5mg, 3 times per day, oral administration) before surgery
groups (𝑛 = 20 per group); and a combination of isoflurane
preconditioning (Iso) and captopril pretreatment (1 hour or
3 days before surgery) (group Cap1hr+Iso or Cap3d+Iso; 𝑛 =
20 per group). Subjects were assigned treatment numbers in
ascending chronological order of admission in the study.The
surgeons, research assistants, andmedical and nursing staff in
the operation room were blinded to the group assignments,
facilitated by covering the drug infusion pump and lines and
shielding the isoflurane vaporizer from view.
The exclusion criteria were (a) cardiogenic shock, (b)
left main coronary artery occlusion or severe stenosis, (c)
blood flow in the infarct-related artery > thrombolysis in
myocardial infarction grade 1, (d) treatment with glycopro-
tein IIb/IIIa receptor antagonists before the procedure, and
(e) infection or surgery within 2 weeks [6, 26].
2.2. Anesthetic Protocols and Surgery. All patients received
standard premedication of scopolamine at 0.006mg/kg of
body weight and morphine at 0.1mg/kg of body weight
intramuscularly 60min before surgery. In all groups, anaes-
thesia was induced with etomidate at 0.3mg/kg of body
weight, fentanyl at 8 𝜇g/kg of body weight, and pancuronium
bromide at 0.1mg/kg of body weight given intravenously.
After induction, all patients received continuous infusions of
fentanyl at 0.6 𝜇g⋅kg−1 of body weight⋅min−1 and pancuro-
nium bromide at 15 𝜇g⋅kg−1 of body weight⋅min−1 during
surgery. The anaesthesia protocol in various groups is as
follows (see Figure 1): anaesthesia wasmaintained either with
fentanyl and midazolam (group control, Cap1hr, and Cap3d)
or with isoflurane 1.1 MAC (minimum alveolar anesthetic
concentration) end tidal before surgery (group Cap1hr+Iso
or Cap3d+Iso). During anaesthesia, patients were monitored
with five-lead ECG, pulse oximetry, capnography, invasive
arterial pressure, and pulmonary artery pressure during the
operation.
Central venous blood sampleswere obtained prior toCPB
(Baseline), 20min after CPB induction, 30min, 4 h, and 24 h
after aortic declamping for themeasurements of plasma levels
of cTnI (cardiac troponin I) and CK-MB (creatine kinase
MB), TNF- (tumor necrosis factor-) 𝛼, IL- (interleukin-) 6,
and ICAM (intercellular adhesion molecule). Samples were
immediately cooled to 4∘C and centrifuged at 1000 g for
10min at 4∘C. Plasma was collected and stored at −70∘C until
analyzed.
2.3. Animal Study Experimental Protocol. The study was
approved by the institutional ethic committee and conforms
with U.S. National Institutes of Health guidelines. Adult
New Zealand white rabbits (1.8 kg) were anaesthetized with
sodium pentobarbital (30mg/kg, Alfasan, Holland). The
rabbits were ventilated with 100% oxygen and end tidal PCO
2
were maintained between 35 and 45mmHg. Myocardial
ischemia reperfusion (I/R) was produced by exteriorizing
the heart through a left thoracic incision and occluding the
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Figure 1: Protocol used in experimental groups. Patients were pretreated without or with captopril for 1 hour (Cap1hr, 12.5mg, oral
administration) or 3 days (Cap3d, 12.5mg, 3 times per day, oral administration) before surgery. After induction, all patients received
continuous infusions of fentanyl at 0.6 𝜇g⋅kg−1 of body weight⋅min−1 and pancuronium bromide at 15𝜇g⋅kg−1 of body weight⋅min−1 during
surgery. The anaesthesia protocol in various groups is as follows: anaesthesia was maintained either with fentanyl and midazolam (group
control, Cap1hr, and Cap3d) or with isoflurane 1.1 MAC (minimum alveolar anesthetic concentration) end tidal before surgery (group
Cap1hr+Iso or Cap3d+Iso).
LAD (left anterior descending artery) with a silk slipknot.
After 40min of ischemia, the slipknot was released and the
myocardium was reperfused for 4 hrs. Sham (sham operated
control rabbits) underwent the same surgical procedures
except that the LAD was not occluded.
Rabbits were randomized to receive one of the following
treatments (𝑛 = 8 each): Sham, rabbits receiving vehicle
(0.9% NaCl) without being subjected to I/R; I/R, rabbits
receiving vehicle during reperfusion; IPC, rabbits receiving
IPC (3 cycles of 10 s of coronary artery reocclusion and
reperfusion) before ischemia; Iso, rabbits receiving isoflurane
(15min 1.1% end tidal isoflurane followed by a 15minwashout
period) before inducing ischemia; Cap, rabbits receiving
captopril (25mg/kg, oral administration) 24 hours before
inducing ischemia; Iso+Cap, rabbits receiving isoflurane in
combination with captopril before inducing ischemia.
2.4. Determination of Myocardial Functional Recovery in Rab-
bits. In the rabbits, LV function was continuously monitored
during the entireMI/R period via aMillarMikro-Tip catheter
pressure transducer inserted into the LV via left carotid
artery as we have described previously. HR (heart rate), MAP,
and RPP were derived by computer algorithms (Chengdu
Instrument).
2.5. Determination of Postischemic Myocardial Infarct Size
in Rabbits and Cellular Injury. The infarct size was mea-
sured with a double-staining technique using Evans Blue-
TTC (Triphenyltetrazolium Chloride) staining and a digital
imaging system, as described previously (additional 𝑛 = 8
rabbits per group were used for infarct size determination).
Blood samples were drawn before ligation and at the end of
reperfusion. Plasma cTnI (cardiac-specific troponin I) from
rabbits and patients were measured spectrophotometrically
(Backman DU 640 instrument) with commercially available
assay kits (Nanjing Jiancheng). The plasma samples were
coded, and the levels of cTnI (cardiac specific troponin I)
were assayed in duplicate by an investigator initially blinded
to the research groups. Plasma IL-6, ICAM, TNF-𝛼, and CK-
MB were measured using ELISA kits (R&D Systems). Plasma
samples used for biochemical assays were coded, and the
laboratory investigator was blinded in regard to treatment
regimen. All haemodynamic data were collected by trained
observers who did not take an authorship in this study and
who were blinded to the methods regarding anaesthetic and
captopril usage.
2.6. Assessment of Rabbit Myocardial Apoptosis by Flow
Cytometry Analysis. At the end of reperfusion, hearts were
removed and washed twice with ice-cold phosphate-buffered
saline; cell suspensions were prepared using the Medima-
chine System (Becton-Dickinson). Cardiomyocyte cells were
collected by flow cytometry with the use of an antibody to
a-sarcomeric actin. The cells were resuspended in binding
buffer, after adding FITC-Annexin V and propidium iodide,
the mixture was incubated for 10 minutes in the dark at 4∘C,
and then cellular fluorescence was measured with a fluo-
rescence activated cell sorter scan flow cytometer (Becton,
Dickinson and Company, Franklin Lakes, NJ) as described
[27].
2.7. Determination of MDA (Malondialdehyde) and SOD
(SuperoxideDismutase) in Rabbit. MDA is end product of the
ROS- (reactive oxygen species-) mediated lipid peroxidation
cascade. Rabbit blood samples were collected, and the MDA
levels weremeasuredwith a commercial kit (Baster Biological
Tech), expressed as nmol/mL. SOD activity was detected in
cardiac tissue homogenates using commercially available kit
(Cayman Chemical) as described previously, expressed as
U/mL.
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2.8. Western Blot Analysis. Equal amount of proteins from
rabbit heart homogenate was resolved by 7.5–15% sodium
dodecyl sulfate polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes and processed as
described. The primary antibodies against BCL-2, Bax, and
GAPDH were purchased from Cell Signaling Technology
(Beverly, MA). Immunoreactive bands were visualized by
enzymatic chemiluminescence method and quantified with
Quantity One image software.
2.9. Sample Size Estimation. Group sample sizewas estimated
based on differences in cTnI concentration measured at 4 h
after CPB in a pilot study of patients who received isoflu-
rane (1–1.5 minimum alveolar concentration throughout the
surgery) anaesthesia. The formula 𝑛 = 15.7/ES2 + 1, where
ES = effect size = (difference between groups)/(mean of the
S.D. between groups), with 𝛼 = 0.05 and power = 0.8,
was used to determine that the study would be adequately
powered with 𝑛 = 20 per group.
2.10. Statistical Analysis. All continuous data are expressed
as means ± SD. Statistical evaluation of patients’ file and
perioperative data was performed by unpaired Student’s
𝑡-test or 𝜒2 test when appropriate. Between-groups and
within-groupdifferences of bioassay datawere analyzed using
two-way ANOVA with repeated measures and Bonferroni’s
corrections (Graphpad Prism). Values were considered sta-
tistically significant when 𝑃 < 0.05.
3. Results
3.1. Human Study Data
3.1.1. Preoperative and Intraoperative Data in Patients. As
shown in Table 1. The patients’ baseline demographics, clini-
cal measures of cardiac function, and medications (digoxin
and diuretic) did not differ among groups. As shown in
Table 2, the operation time, aortic clamping time, and bypass
time did not differ among groups. Automatic rebeating rate in
groups Cap3d+Iso and Cap1hr+Iso was significantly higher
than that in control group, while no significant difference
was observed in groups Cap3d and Cap1hr as compared
to control group. Arrhythmia incidence was significantly
higher in control group than that in all treatment groups
(Cap3d+Iso, Cap1hr+Iso, Cap3d, and Cap1hr) and there is no
difference among all treatment groups. Similarly, dopamine
usage was significantly reduced in all treatment groups
comparedwith the control groups and therewas no difference
among all treatment groups. Sodium nitroprusside usage
was significantly reduced in all treatment groups compared
with the control groups and sodium nitroprusside usage was
significantly reduced in group Cap3d+Iso relative to other
groups.
3.1.2. Postoperative Outcome Data in Patients. As shown in
Table 2, durations of postoperative ICU stay in all treatment
groups were shorter than that in the control group, and
durations of postoperative ICU stay in groups Cap3d+Iso
andCap1hr+Iso were significantly shorter than that in groups
Cap3d and Cap1hr. The duration of hospital stay in group
Cap3d+Iso, but not groups Cap3d or Cap1hr, was shorter
than that in Cap1hr+Iso and the duration of hospital stay
in all treatment was significantly reduced compared with
control group. All patients were discharged from hospital
uneventfully.
3.1.3. Isoflurane and Captopril Attenuated Postischemic Myo-
cardial Cellular Injury and Reduced Proinflammatory Cy-
tokines TNF-𝛼, IL-6, and ICAM in Patients. Baseline plasma
levels of cTnI, CK-MB, TNF-𝛼, IL-6, and ICAMdid not differ
among groups, but all significantly increased in control group
both during CPB and during reperfusion at 30 minutes and 4
hours after CPB (Figures 2(a)–2(e)), while post-CPB plasma
levels of CK-MB, TNF-𝛼, IL-6, and ICAMdid not differ from
that in baseline (Figures 2(b)–2(e)). During CPB and during
reperfusion at 30 minutes, 4 hours, and 24 hours after CPB,
plasma levels of cTnI, CK-MB, TNF-𝛼, IL-6, and ICAM in
Cap3d+Iso, Cap1hr+Iso, and Cap3d, but not in Cap1hr, were
significantly lower than that in the control groups, and those
in group Cap3d+Iso and Cap1hr+Iso were significantly lower
than that in other groups (Figures 2(a)–2(e)). Plasma levels
of cTnI during CPB and during reperfusion at 30 minutes,
4 hours, and 24 hours after CPB in group Cap3d+Iso were
significantly lower than that in Cap1hr+Iso (Figure 2(a)).
3.2. Animal Study Data
3.2.1. Isoflurane and Captopril Reduced Postischemic Myocar-
dial Injury, Ameliorated Myocardial Inflammation, and At-
tenuated Cardiac Ultrastructural Alterations in Rabbits. As
shown in Figure 2, the myocardial area at risk did not differ
among groups (Figure 3(a)). I/R resulted in significantly
increased myocardial IS in I/R group. IPC, Iso, or Cap
alone significantly reduced IS, while Cap in combination
with Iso (Cap+Iso group) yielded an additive effect in that
they further decreased IS as compared with either Iso or
Cap alone (Figure 3(b)). Biopsies taken from sham operated
control rabbit heart showed basically normal ultrastructure,
with regular intercalated disks, sarcomere preservation, and
normal mitochondrial morphology, although mild cytosolic,
intermyofibrillar edema, and nuclear chromatin margination
could occasionally be seen. In contrast, biopsies taken after
postischemic reperfusion from rabbit heart showed signs of
injury; in particular, cytosolic and intermyofibrillar edema
was moderate to marked, and mitochondria showed more
extensive damage compared with that in sham operated
group. Biopsies taken from IPC, Cap, Iso, and Cap+Iso
groups showed normal myofibrillar ultrastructure and mild
separation of the mitochondrial cristae without swelling and
vacuolation (Figure 3(c)).
3.2.2. Isoflurane andCaptopril Improved PostischemicMyocar-
dial Function Recovery in Rabbits. As shown in Figure 3,
heart rate in groups Iso and Cap+Iso was significantly
higher than that in other groups at baseline, and during
ischemia, and during reperfusion at reperfusion 30 minutes,
respectively, while no significant difference was observed
among groups during reperfusion at reperfusion 60 minutes
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Table 1: Baseline characteristics of the study population.
Item Control Cap1hr Cap3d Cap1hr+Iso Cap3d+Iso
Gender (male/female) 14/6 14/6 15/5 13/7 14/6
Age (years) 46.2 ± 5.9 46.8 ± 7.5 44.5 ± 6.9 43.2 ± 7.2 45.3 ± 6.1
Body weight (Kg) 58.2 ± 7.2 61.7 ± 8.1 62.1 ± 9.0 61.2 ± 7.9 59.7 ± 8.3
LVEF (%) 55.2 ± 6.9 55.3 ± 6.9 53.1 ± 7.8 54.2 ± 7.4 56.6 ± 6.3
Premedication
Digoxin (𝑛) 6 6 7 5 6
Diuretic (𝑛) 8 7 6 7 8
Control: untreated control; Cap1hr: captopril treatment for 1 h before surgery (12.5mg, p.o., 1 h before surgery); Cap3d: captopril treatment for 3 days (12.5mg,
p.o., 3 times a day) before surgery; Cap1hr+Iso: captopril treatment for 1 h in combination with inhalational isoflurane (Iso) at 1.1% end tidal concentration
administrated for 30min before CPB; Cap3d+Iso: captopril treatment for 3 days in combination with Iso before CPB. Values are means ± S.D. or the number
of patients. No significant differences were observed among groups; LVEF: left ventricular ejection fraction.
Table 2: Intraoperative and postoperative procedure characteristics of the patients.
Item Control Cap1hr Cap3d Cap1hr+Iso Cap3d+Iso
Operation time (min) 147 ± 43 147 ± 45 142 ± 41 144 ± 45 148 ± 42
Aortic clamping time (min) 46 ± 18 46 ± 17 45 ± 19 47 ± 16 43 ± 18
Bypass time (min) 65 ± 19 67 ± 19 68 ± 20 67 ± 22 68 ± 21
Automatic rebeating rate (%) 40 50# 50# 70∗ 80∗
Arrhythmia incidence (%) 45 35∗ 35∗ 30∗ 20∗
Dopamine (mg) 687 ± 63 513 ± 71∗# 478 ± 67∗# 317 ± 46∗ 243 ± 54∗#
Sodium nitroprusside (mg) 813 ± 64 796 ± 66# 749 ± 81# 706 ± 83∗ 641 ± 83∗#
ICU stay (h) 68.6 ± 9.1 62.0 ± 8.9∗# 59.1 ± 8.8∗# 54.5 ± 8.9∗ 43.1 ± 9.3∗
Hospital stay (d) 16.2 ± 2.5 14.69 ± 2.9∗# 13.2 ± 2.8∗ 12.8 ± 2.1∗ 10.3 ± 1.6∗#
Death in hospital (𝑛) 0 0 0 0 0
Control: untreated control; Cap1hr: captopril treatment for 1 h before surgery (12.5mg, p.o., 1 h before surgery); Cap3d: captopril treatment for 3 days (12.5mg,
p.o., 3 times a day) before surgery; Cap1hr+Iso: captopril treatment for 1 h in combination with inhalational isoflurane (Iso) at 1.1% end tidal concentration
administrated for 30min before CPB; Cap3d+Iso: captopril treatment for 3 days in combination with Iso before CPB. Values are means ± S.D. or the number
of patients. ∗
𝑃
< 0.05 versus Control, #
𝑃
< 0.05 versus Cap1hr+Iso.
and 120 minutes (Figure 4(a)). Mean arterial pressure (MAP)
in groups Iso and Cap+Iso was significantly lower than that
in other groups and did not differ between groups in baseline,
ischemia for 30 minutes, reperfusion for 30 minutes, and
reperfusion for 60 minutes, and no significant differences
of MAP were observed among groups (Figure 4(b)). Rate
pressure product (RPP) in groups Iso and Iso+Cap was
significantly lower than that in other groups at baseline,
during I/R, and reperfusion, while there was no difference
between Iso and Iso+Cap groups (Figure 4(c)).
3.2.3. Isoflurane and Captopril Attenuated Postischemic Myo-
cardial Apoptosis in Rabbits. Bcl-2, an antiapoptotic protein,
was moderately increased in I/R groups but was significantly
increased in IPC, Iso, Cap, and Iso+Cap groups, and Bcl-2 in
IPC and Iso+Cap groups were significantly higher than that
in Iso or Cap groups (Figure 5(a)). Proapoptotic protein Bax
was significantly increased in I/R and significantly reduced
in IPC, Iso, Cap, and Iso+Cap groups, and there was no sig-
nificant difference among IPC, Iso, Cap, and Iso+Cap groups
(Figure 5(b)). Bcl-2/Bax ratio was significantly reduced in
I/R group compared with Sham group. Bcl-2/Bax ratio was
enhanced by IPC, Iso, Cap, and Iso+Cap as compared to
control, and IPC and Iso+Cap significantly further increased
Bcl-2/Bax ratio comparedwith Iso or Cap alone (Figure 5(c));
the respective protein expressions were further confirmed by
flow cytometry (Figures 5(d) and 5(e)).
3.2.4. Isoflurane and Captopril Ameliorated PostischemicMyo-
cardial Oxidative Stress in Rabbits. MDA, an index of lipid
peroxidation, was significantly increased in I/R and was
moderately reduced in IPC, Iso, Cap, and Iso+Cap groups
relative to I/R groups (Figure 6(a)). Plasma SOD in I/R group
was significantly lower as compared to sham operative group,
and IPC, Iso, Cap, and Iso+Cap slightly increased SOD as
compared to I/R but the difference did not reach statistical
difference (Figure 6(b)).
4. Discussion
The novel finding of the present clinical and animal studies
is that the application of 3-day captopril treatment, but not 1-
hour captopril treatment, in combinationwith isoflurane pre-
conditioning before prolonged index ischemia was superior
to either captopril treatment (3 days or 1 hour) or isoflurane
alone in reducing postischemic myocardial oxidative stress,
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Figure 2: Isoflurane (Iso) and captopril (Cap) attenuated postischemic myocardial cellular injury and reduced proinflammatory cytokines
release in patients. (a) Plasma cardiac troponin I (cTnI), (b) plasma creatine kinase- (CK-)MB, (c) plasma tumor necrosis factor- (TNF-)𝛼, (d)
plasma interleukin- (IL-) 6, and (e) plasma intercellular adhesion molecule (ICAM). Control: untreated control; Cap1hr: captopril treatment
for 1 h before surgery (12.5mg, p.o., 1 h before surgery); Cap3d: captopril treatment for 3 days (12.5mg, p.o., 3 times a day) before surgery;
Cap1hr+Iso: captopril treatment for 1 h in combination with inhalational isoflurane (Iso) at 1.1% end tidal concentration administrated for
30min before CPB; Cap3d+Iso: captopril treatment for 3 days in combination with Iso before CPB. Data are shown as means ± SD, with
𝑛 = 20 per group. #𝑃 < 0.05 versus Baseline, ∗𝑃 < 0.05 and $𝑃 < 0.01 versus Control, and &𝑃 < 0.05 versus Cap1hr+Iso.
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Figure 3: Isoflurane (Iso) and captopril (Cap) reduced postischemicmyocardial injury, amelioratedmyocardial inflammation, and attenuated
cardiac ultrastructural alterations in rabbits. (a) Ratio of area at risk (AAR) to left ventricular (LV), (b) percentage of infarct size (IS) expressed
as a percentage of AAR, (c) representative images of electron micrograph of rabbit hearts, (d) plasma cTnI, (e) plasma CK-MB, and (f) lactate
dehydrogenase (LDH). Sham: sham operated control; I/R: rabbits subjected to myocardial ischemia reperfusion (MI/R); Cap: rabbits treated
with captopril (25mg/kg given intravenously 24 h) prior to inducing MI/R; Iso: rabbits received isoflurane preconditioning (15min 1.1% end
tidal isoflurane followed by a 15min washout period before inducing MI/R); Iso+Cap: rabbits received captopril in combination with Iso.
Data are shown as means ± SD, with 𝑛 = 8 animals per group. #𝑃 < 0.05 or 𝑃 < 0.01 versus I/R, ∗𝑃 < 0.05 versus IPC, and &𝑃 < 0.05 versus
Baseline.
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Figure 4: Isoflurane (Iso) and captopril (Cap) improved postischemic myocardial function recovery in rabbits. (a) Heart rate, (b) mean
arterial pressure (MAP), and (c) rate pressure product (RPP) at baseline and during ischemia and reperfusion. Sham: sham operated control;
I/R: rabbits subjected to myocardial ischemia reperfusion (MI/R); Cap: rabbits treated with captopril (25mg/kg given intravenously 24 h)
prior to inducingMI/R; Iso: rabbits received isoflurane preconditioning (15min 1.1% end tidal isoflurane followed by a 15min washout period
before inducing MI/R); Iso+Cap: rabbits received captopril in combination with Iso. Data are shown as means ± SD, with 𝑛 = 8 animals per
group. #𝑃 < 0.05 or 𝑃 < 0.01 versus Sham, ∗𝑃 < 0.05 versus Baseline.
proinflammatory cytokines release, and myocardial injury.
Combinational use of captopril as well as isoflurane precon-
ditioning confers antioxidative stress and anti-inflammatory
effects not only during ischemia but also during reperfusion
stage in patients undergoing CPB. To our knowledge, this
is the first study to demonstrate that captopril and isoflu-
rane preconditioning can additively attenuate myocardial
ischemia reperfusion (MI/R) injury.
When ischemia occurs, the oxygen and nutrient supply to
the myocardium is reduced due to the decrease of blood flow.
This deprivation of oxygen as well as nutrient supply results
in the accumulation of sodium, hydrogen, and calcium ions,
culminating in tissue acidosis, which leads to mitochondrial
membrane depolarization, ATP depletion, and inhibition
of myocardial contractile function [28]. Reperfusion, in
turn, elicits rapid alterations in ion flux, stimulates a robust
formation of ROS [29], and promotes the proinflamma-
tory cytokines release [30], which eventually results in or
exacerbates MI/R injury [31, 32]. Modulation of the early
events induced by ischemia is of particular importance in
combating MI/R. In the present study, in patients with CPB,
a joint use of captopril and isoflurane preconditioning sig-
nificantly reducedMI/R-induced proinflammatory cytokines
(TNF-𝛼, IL-6, and ICAM-1) release during CPB, which
was associated with reduced myocardial injury during CPB
and after CPB (reperfusion), and this protective effect of
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Figure 5: Isoflurane (Iso) and captopril (Cap) attenuated postischemic myocardial apoptosis in rabbits. (a) Protein expression of cardiac
Bcl-2, (b) protein expression of cardiac Bax, (c) ratio of Bcl-2 to Bax, (d) representative graphs showing the proportion of apoptotic
myocytes, and (e) quantitation of apoptoticmyocytes. Sham: shamoperated control; I/R: rabbits subjected tomyocardial ischemia reperfusion
(MI/R); Cap: rabbits treated with captopril (25mg/kg given intravenously 24 h) prior to inducing MI/R; Iso: rabbits received isoflurane
preconditioning (15min 1.1% end tidal isoflurane followed by a 15min washout period before inducing MI/R); Iso+Cap: rabbits received
captopril in combination with Iso. Data are shown as means ± SD, with 𝑛 = 8 animals per group. #𝑃 < 0.05 versus I/R, ∗𝑃 < 0.05 versus
IPC.
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Figure 6: Isoflurane (Iso) and captopril (Cap) ameliorated postischemic myocardial oxidative stress in rabbits. (a) Cardiac malondialdehyde
(MDA) content, (b) plasma superoxide dismutases (SOD) levels. Sham: sham operated control; I/R: rabbits subjected to myocardial ischemia
reperfusion (MI/R); Cap: rabbits treated with captopril (25mg/kg given intravenously 24 h) prior to inducing MI/R; Iso: rabbits received
isoflurane preconditioning (15min 1.1% end tidal isoflurane followed by a 15min washout period before inducing MI/R); Iso+Cap: rabbits
received captopril in combination with Iso. Data are shown as means ± SD, with 𝑛 = 8 animals per group. #𝑃 < 0.05 versus Sham, ∗𝑃 < 0.05
versus I/R, and &𝑃 < 0.05 versus IPC.
captopril in combination of isoflurane preconditioning is
superior to captopril treatment for 3 days or 1 hour alone.
Solenkova et al. reported that, in isolated rabbit heart model,
cardioprotection of ischemic preconditioning is dependent
on activation of adenosine receptors during the first minutes
of reperfusion following termination of the index ischemia
[33]. Similarly, Kin et al. showed that the first minute of
the onset of reperfusion is critical to the cardioprotective
effects of ischemic postconditioning, which protects the heart
against MI/R injury by inhibiting oxidant generation and
oxidant mediated injury in rats [34]. These together with the
results from our present study jointly support the notion that
inhibition of myocardial oxidative stress and inflammation
occurred during ischemia or in the early minutes at the onset
of reperfusion is important for developing cardioprotective
strategies against MI/R. Results from our present study pro-
vide a clue that inhibition of myocardial oxidative stress and
inflammation as early as during ischemia plays a pivotal role
in amelioratingmyocardial injury inMI/R.Of note, in animal
study, captopril, isoflurane, and their combination all mimic
the protective effects of IPC in reducing myocardial injury
during ischemia, while there is no significant difference
observed among all treatment groups (IPC, Cap, Iso, and
Iso+Cap). This is not consistent with the results seen in our
human study which showed that additive effects of captopril
and isoflurane preconditioning exist as early as ischemia
induction (CPB).One possible explanation is that the severity
of MI/R injury is different between patients with CPB and
animals receivedMI/R in the current study and that captopril
treatment for 24 hours in animals may not precisely mimic
that in our human study (3 days or 1 hour before CPB).
Increased oxidative stress and evaluated inflammation
have been suggested as the main cause of MI/R injury.
We previously showed that antioxidant N-acetylcysteine and
allopurinol confer cardioprotective effects in rat subjected
to MI/R [29, 35] and isoflurane preconditioning and propo-
fol postconditioning synergistically reduced MI/R injury in
patients undergoing CPB by upregulating endothelial nitric
oxide synthase protein expression and reducing oxidative
stress and proinflammatory cytokines release [6]. Similarly, in
the present study, in animal model of MI/R, captopril, isoflu-
rane preconditioning, and their combination all reduced
MDA (marker of lipid peroxidation) and increased SOD
activity, which were accompanied with decreased myocyte
apoptosis and reduced myocardial injury and inflammation.
Captopril in combination with isoflurane preconditioning
confers superior protection to either captopril or isoflurane
alone in rabbits subjected to MI/R. However, in patients
with CPB, captopril (3 days or 1 hour) in combination with
isoflurane preconditioning and captopril treatment alone, for
3 days but not 1 hour, reduced MI/R injury and mycocar-
dial inflammation. This inconsistence suggests that captopril
cardioprotective effects maybe depend on the duration of
the treatment. van den Heuvel et al. demonstrated that
captopril treatment for 3 months reduces the incidence of
ischemia-related events after myocardial infarction, but a
high incidence of clinical events occurred with withdrawal
from captopril after 3-month treatment relative to 1-year
captopril treatment [36]. This is consistent with our present
finding that no cardioprotective effect was observed in
patients treated with captopril 1 hour before CPB, while 3-
day captopril treatment exerted profound protection. It is of
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notice that, although captopril treatment for 1 hour alone did
not show a protective effect in patients underwent CPB in
the current study, captopril treatment for 1 hour in combina-
tion of isoflurane preconditioning conferred cardioprotective
effects, indicating that captopril treatment may facilitate
isoflurane preconditioning to confer protection. Captopril
by inhibiting angiotensin-converting enzyme activity reduces
the degradation of bradykinin, resulting in enhanced for-
mation of prostacyclin and nitric oxide (NO), consequently
exerting its antioxidant and anti-inflammatory properties
[20, 24] and conferring cardioprotective effects [25]. NO
has been proven as a trigger and mediator of isoflurane
preconditioning cardioprotection. Isoflurane precondition-
ing by increasing endothelial nitric oxide synthase (NOS),
but not inducible or neuronal NOS, enhances NOproduction
and confers cardioprotection in a rabbit MI/R model [37].
These together suggest that captopril and isoflurane precon-
ditioning can confer additive/synergistic effects in combating
MI/R. This is confirmed in our present clinical study and
animal study. However, further study is needed to elucidate
the specific molecular mechanism governing the synergy of
captopril and isoflurane preconditioning in the setting of
MI/R.
5. Conclusions
In summary, we demonstrated that isoflurane precondition-
ing, combined with captopril treatment (3 days but not 1
hour), acts additively in attenuating postischemicmyocardial
reperfusion injury as determined by the surrogate markers
of myocardial injury and function. Further large-scale and
long-term studies are required to confirm the clinical benefit
of this novel pharmacologic regimen, which may offer a
promising therapeutic approach to cardioprotection patients
undergoing cardiac surgery.
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